Table 1 Clinical data and demographic of patients (n = 63) who underwent 18F-FDG total-body PET/CT with ultra-low activity injection
Characteristic | Underweight (n = 12) | Normal (n = 20) | Overweight (n = 20) | Obese (n = 11) | P |
|---|---|---|---|---|---|
Age (years) | 56.7 ± 17.3 | 62.1 ± 12.8 | 63.3 ± 12.6 | 61.8 ± 7.9 | 0.77 |
Sex | Â | Â | Â | Â | 0.30 |
Male | 8 | 12 | 12 | 10 | Â |
Female | 4 | 8 | 8 | 1 | Â |
BMI (kg/m2) | 17.2 ± 0.6 | 22.8 ± 1.8 | 26.6 ± 1.4 | 31.4 ± 1.4 |  < 0.0001 |
Blood glucose before injection (mmol/L) | 5.6 ± 0.7 | 5.7 ± 0.9 | 6.1 ± 1.3 | 6.0 ± 0.7 | 0.53 |
Injected dose (MBq) | 18.6 ± 1.9 | 24.0 ± 3.0 | 27.4 ± 4.0 | 34.2 ± 5.1 |  < 0.0001 |
Acquisition time (min) | 62.8 ± 9.6 | 63.1 ± 7.5 | 63.3 ± 9.4 | 60.8 ± 9.6 | 0.87 |
Clinical stages | Â | Â | Â | Â | 0.54 |
I | 2 | 6 | 3 | 2 | Â |
II | 4 | 5 | 3 | 2 | Â |
III | 2 | 5 | 8 | 4 | Â |
IV | 4 | 4 | 6 | 3 | Â |